WebMD

How Skyrizi Works for Plaque Psoriasis

Although many people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...
WebMD

Skyrizi: FDA Approves Pediatric Expansion of IL‑23 Inhibitor for Moderate-to-Severe Plaque Psoriasis and Active Psoriatic Arthritis

What Is Skyrizi, and Why Does It Matter? Skyrizi (risankizumab-rzaa) is a prescription biologic used to treat certain immune-mediated inflammatory conditions. It is now approved by the FDA for ...
Morningstar

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

NORTH CHICAGO, Ill., April 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for ...
Morningstar

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of ...
Nasdaq

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Submission supported by data from Phase 3 pivotal AFFIRM study If approved, adult Crohn's disease patients will have an additional option for induction of risankizumab-rzaa which is already approved ...